Eton Pharmaceuticals (ETON): Director sold ~$1.5M

~$1.5M

Approx. value · 23K sh @ $66.26

37K

Holds after · shares reported

Traded

Nov 10, 2026

Filed

Nov 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 6, 2026InsiderOfficer sold ~$229K of ETON shares in the open market
2. Oct 14, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and signed an important agreement“As disclosed in Item 1.01, on October 13, 2026, the Company entered into an exclusive license agreement and a supply agreement covering the United States and its territories for LIBERVANT® (diazepam) buccal film , an orphan-designated, differentiated treatment for seizure clusters in patients with epilepsy with Aquestive.”
3. Nov 5, 2026Company filing · Form 8-K · ResultsReported its results
4. Nov 6, 20265% stakeOpaleye Management Inc. reported a passive stake (13G) of 8.5%
5. Nov 10, 2026 · this disclosureInsiderDirector sold ~$1.5M of ETON shares in the open market

What came next

1. Nov 10, 2026Insider · 2 peopleInsiders: 6 sales (~$4.1M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eton Pharmaceuticals

For Eton Pharmaceuticals, OQRO holds 11 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ETON page.

Other recent filings by Charles J Casamento, Director

• SEC Form 4 at Eton Pharmaceuticals (ETON)Nov 10, 2026
• SEC Form 4 at Eton Pharmaceuticals (ETON)Nov 10, 2026
• SEC Form 4 at Eton Pharmaceuticals (ETON)Nov 10, 2026
• SEC Form 4 at Eton Pharmaceuticals (ETON)Nov 10, 2026

The full history of Charles J Casamento, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Eton Pharmaceuticals

• SEC Form 4Nov 12, 2026
• SEC Form 4Nov 12, 2026
• SEC Form 144Nov 10, 2026
• SEC Form 144Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 4Nov 10, 2026

Everything OQRO holds on this company is on its ETON page.